Zymergen
Zymergen raises $130M Series C at $560M valuation
Quick Facts
Zymergen: Series C Funding Round
Zymergen has successfully raised $130M in Series C funding, reaching a valuation of $560M.
Company Overview
Bio-based materials and molecule development
Funding Details
The Series C round was led by SoftBank Vision Fund, with participation from Data Collective.
Company Information
- Headquarters: Emeryville, CA
- Founded: 2013
- Employees: 500+
- Category: Biotech
Investment
Zymergen plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series C
- Data Collective: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
